Article
Paris-Neurotech SA is initiating a phase I clinical trial of NT-501, its lead Encapsulated Cell Technology (ECT) product for the treatment of retinitis pigmentosa (RP).
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.